Richter's syndrome

7 trials 5 recruiting MedDRA PT
7 Registered trials
5 Recruiting
6 Unique sponsors
16 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 4
N Neurology/Psychiatry (ATC N) 1
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
BTK inhibitor 3 substances
Unknown / small molecule 2 substances
Monoclonal antibody (tumor, humanized) 2 substances
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
BCL-2 inhibitor 1 substance
Alkylating agent 1 substance
Anthracycline 1 substance
Corticosteroid 1 substance
Monoclonal antibody (chimeric) 1 substance
Vinca alkaloid 1 substance
Phase II: 3 Phase I/II: 2 Phase I: 1 Phase I (First in Human): 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase II

3 trials
  • Merck Sharp & Dohme LLC Commercial
    NEMTABRUTINIB; ZILOVERTAMAB VEDOTIN
    2022-501374-19-00 9 countries 2022 n=103
    Recruiting
  • ASST Grande Ospedale Metropolitano Niguarda Academic
    ATEZOLIZUMAB; OBINUTUZUMAB; VENETOCLAX
    2024-516675-32-00 1 country 2019 n=14
    Ended
  • French Innovative Leukemia Organization Academic
    CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; GLOFITAMAB; OBINUTUZUMAB; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE
    2022-501554-11-00 1 country 2024 n=40 Orphan
    Recruiting

Phase I/II

2 trials
  • Acerta Pharma B.V. Commercial
    ACALABRUTINIB
    2023-509346-35-00 1 country 2015 n=1
    Ended
  • BeOne Medicines AG Commercial
    BGB-16673; GLOFITAMAB; MOSUNETUZUMAB; N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5- YL)OXY]BENZAMIDE; OBINUTUZUMAB; ZANUBRUTINIB
    2024-516234-35-00 3 countries 2025 n=99 Orphan
    Recruiting

Phase I

1 trial
  • Exscientia AI Limited Commercial
    IMP not specified
    2024-516869-36-00 5 countries 2025 n=101
    Recruiting

Phase I (First in Human)

1 trial
  • BeOne Medicines AG Commercial
    IMP not specified
    2022-502157-33-00 5 countries 2023 n=239
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
BeOne Medicines AG Commercial 2 Phase I (First in Human), Phase I/II 2
Exscientia AI Limited Commercial 1 Phase I 1
Merck Sharp & Dohme LLC Commercial 1 Phase II 1
Acerta Pharma B.V. Commercial 1 Phase I/II 0
ASST Grande Ospedale Metropolitano Niguarda Academic 1 Phase II 0
French Innovative Leukemia Organization Academic 1 Phase II 1
New trials by year
2019
1
2022
1
2023
1
2024
1
2025
2
← All indication landscapes